Pyrimethamine-sulfadoxine (Fansidar) resistance in a non-immune Kenyan--a case report.
Drug resistance in an endemic zone is often difficult to prove. This case illustrating both chloroquine and pyrimethamine sulfadoxine resistance unfolded in an area without risk of reinfection. The long time lapse and hence danger, between exposure and clinical symptoms in those on chemoprophylaxis highlighted and emphasis is placed on adequate follow up to pick up resistance in long acting preparations.
Nevill
C G
CG
Malaria Unit, African, Medical Research Foundation (AMREF), Nairobi, Kenya.
Gardner
A
A
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002648:Child; D002738:Chloroquine / Q000494:pharmacology*; D004338:Drug Combinations; D004351:Drug Resistance; D006801:Humans; D007630:Kenya; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D010963:Plasmodium falciparum; D011739:Pyrimethamine / Q000494:pharmacology*; D013413:Sulfadoxine / Q000494:pharmacology*
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine